What the FDA Personal Importation Policy actually is

If you have searched for information on importing medication for your own use, you have probably seen references to the “FDA Personal Importation Policy” — described, often in the same breath, as both a rule that allows importation and a rule that prohibits it. This page describes what the policy actually is, from the FDA’s own published documents.

What is the FDA Personal Importation Policy?

The FDA Personal Importation Policy is the name commonly used for the framework described in the FDA Regulatory Procedures Manual, Chapter 9, Subchapter 9-2 (“Coverage of Personal Importations”), summarized for the public on the FDA’s “Personal Importation” page.[1][2] It is a guidance document. The opening of the manual states the agency’s position directly: the chapter is intended only to provide operating procedures for FDA personnel and is not intended to create or confer any rights, privileges, or benefits on any private person.[2]

What that means for a patient: the policy tells FDA staff how to decide whether to release a personal-use shipment at the border. It does not give patients a right to import. It does not authorize importation. It does not protect patients who import. It describes the conditions under which FDA staff may choose not to enforce against a particular shipment. For the legal-analysis layer — why enforcement discretion is not the same as “legal” — see the companion page, “Enforcement discretion” is not the same as “legal.”

What does the FDA’s published page actually say?

The FDA’s “Personal Importation” page states that in most circumstances it is illegal for individuals to import drugs into the U.S. for personal use, because products purchased from other countries often have not been approved by the FDA for use and sale in the U.S., and that if a drug is approved abroad but is an unapproved new drug in the U.S., it is illegal to import.[1] That is the FDA’s framing on its own page: the default rule, as the agency describes it, is that personal importation is generally illegal. The framework patients commonly call the “policy” applies only after that default is established.

The agency then describes the exception. In considering personal-use shipments, FDA personnel may consider a more permissive decision in two situations. The first is for products that are not for treatment of a serious condition and present no known significant health risk. The second — the one that matters for patients with chronic conditions — is for prescription drug products meeting all of the following criteria:[1][3]

• The product is for a serious condition for which effective treatment may not be available domestically, either through commercial or clinical means.
• There is no known commercialization or promotion of the product to U.S. residents.
• The product does not represent an unreasonable risk.
• The consumer affirms in writing that the product is for personal use.
• The quantity is generally not more than a three-month supply, and the consumer either names the U.S.-licensed doctor responsible for their treatment with the product, or provides evidence that the product continues a treatment begun in a foreign country.

Two things about how this is phrased. First, the language is that FDA personnel may consider a more permissive decision — not that the FDA “will permit” or “authorizes.” The decision rests with the officer reviewing a particular shipment. Second, the criteria are connective: meeting some but not all of them does not partially qualify a shipment. A shipment that fails any criterion falls outside the framework the FDA has described.

What does “may consider a more permissive decision” mean?

The verbs in the FDA’s guidance are doing important work, and patients often read past them. The manual states that FDA personnel may allow entry of shipments when the quantity and purpose are clearly for personal use and the product does not present an unreasonable risk — while also stating that even though all products appearing to violate the statutes are subject to refusal, FDA personnel may examine the background, risk, and purpose before making a final decision.[3] The manual then adds a clarification patients often skip: although the FDA may use discretion to allow admission of certain violative items, this should not be interpreted as a license to individuals to bring in such shipments.[3]

This is the agency telling readers, directly, that the policy is not a license. The framework describes when FDA personnel may consider a more permissive decision. It does not authorize the conduct itself. Importing an unapproved new drug into the United States remains presumptively prohibited under the new-drug and import provisions of the Federal Food, Drug, and Cosmetic Act.[4][5] Meeting the criteria does not convert the conduct from prohibited to permitted; it only places the shipment within a framework where FDA staff may consider exercising enforcement discretion rather than refusing admission. The legal status of the conduct itself is unchanged.

Why the “no effective U.S. treatment available” criterion matters most

Of the five criteria, the first — that the product is for a serious condition for which effective treatment may not be available domestically — is the one most often misread, and the one that most often fails for cost-driven importation.

Consider a common scenario. A patient is prescribed an FDA-approved medication for a chronic condition. The medication is available in the United States, on pharmacy shelves and within the FDA approval system. The patient cannot afford the U.S. price, and considers importing the same drug — or a generic equivalent — from a country where it costs a fraction as much. Read against the FDA’s criterion: the condition is serious, but effective treatment is available domestically. The barrier is cost, not availability. The shipment does not meet the criterion the FDA has published.

The Congressional Research Service has summarized the agency’s position: the FDA has generally allowed individuals to bring in a 90-day supply of an unapproved drug for personal use where effective treatment is not available in the United States, and the personal-importation policy was not normally intended as a way for consumers to obtain lower-priced prescription drugs.[6] The framework was designed for patients whose condition cannot be treated with anything available in the U.S. — not for patients whose treatment exists but is unaffordable.

This does not mean every cost-driven shipment is refused at the border. It means cost-driven imports of FDA-approved drugs do not fall within the framework the FDA has published. They fall in the broader category of personal-use shipments of unapproved new drugs, which the manual describes as subject to refusal even where enforcement discretion is in play.[3]

The three-month supply benchmark

The published criteria specify that the quantity should generally not exceed a three-month supply. The manual uses this figure to distinguish a personal-use shipment from a commercial one: a supply exceeding roughly three months may be evaluated as commercial, and commercial shipments fall outside the enforcement-discretion framework entirely.[3] The benchmark is not a guarantee — shipments at or below three months may still be refused for failing another criterion, and shipments above it carry a significantly higher risk of being treated as commercial and refused.

What the policy does not cover

Several categories fall entirely outside the framework. These are not edge cases; they are categorical exclusions.

Controlled substances

The FDA’s page states that some medications are also controlled substances, and that the DEA generally makes the decision on whether controlled substances may be imported for personal use; the manual directs that drugs subject to DEA jurisdiction be returned to CBP for handling.[1][3] The FDA enforcement-discretion framework does not apply to them. The companion page on controlled substances addresses this directly.

Drugs subject to FDA Import Alerts

The FDA maintains Import Alerts identifying products, manufacturers, or sources subject to Detention Without Physical Examination. The manual states that drugs, biologics, and devices subject to Import Alerts are generally not amenable to these procedures.[3] Import Alert 66-57 specifically targets foreign-manufactured unapproved prescription drugs distributed to individuals in the United States, including via online pharmacies.[7] Captured shipments are detained automatically and not evaluated against the discretion criteria.

Commercial shipments

A patient ordering from a foreign pharmacy that operates as a commercial supplier to U.S. customers is, from the FDA’s perspective, the recipient of a commercial shipment — regardless of whether that individual purchase was for personal use. The “personal” character of a shipment is determined by the FDA’s assessment of the shipper’s operation, not solely by the recipient’s intent.[3] The companion page on what personal importation is not addresses this.

State pharmacy practice violations

The framework is a federal enforcement posture. It does not preempt state law. A state pharmacy board that prohibits possession of foreign-sourced prescription medication can act against a patient even when the FDA would not. The companion page on state pharmacy boards addresses this layer.

What happens at the border

The manual describes two pathways. For personal baggage, initial responsibility rests with U.S. Customs and Border Protection; FDA personnel do not examine personal baggage, and most personal baggage containing FDA-regulated items is not referred to the FDA at all.[8] For mail and courier shipments, CBP examines parcels at International Mail Facilities and sets aside those appearing to contain drugs, which the FDA then reviews.[9]

Mail shipments face an authority that personal baggage does not. Under the import provisions of the FFDCA, as amended by the FDA Safety and Innovation Act of 2012, the FDA may destroy a refused drug valued at $2,500 or less without offering the usual opportunity to export it, after notice and an opportunity for the consignee to respond.[5][10] The practical implication: a mailed shipment that is refused is not necessarily returned — it may be destroyed. The companion page on border seizures covers this in detail.

The framework is not permanent

Nothing on the FDA’s “Personal Importation” page is a law, and nothing in the manual is a regulation. Both are agency guidance and can be revised, narrowed, or replaced. The framework also sits against a statutory backdrop — Section 804 of the FFDCA, codified at 21 U.S.C. § 384 — that is under active political contest.[11]

Section 804(j) directs the Secretary of Health and Human Services to use enforcement discretion to permit certain personal-use prescription drug imports, but Section 804(l) provides that Section 804 becomes effective only after the Secretary certifies to Congress that implementation would pose no additional risk to public health and would significantly reduce costs to American consumers.[11][12] A certification was made in September 2020 — but only with regard to the wholesale pathway, Section 804(b) through (h), concurrent with the 2020 final rule.[6][13] The personal-importation provisions of Section 804(j) have not been certified and are not in legal effect.[12]

The wholesale pathway operates state-to-pharmacy, not patient-to-foreign-pharmacy. Under it, states or tribes may submit Section 804 Importation Program (SIP) proposals to import certain drugs from Canada.[13] Florida’s SIP is the only state program FDA has authorized, with the original authorization granted January 5, 2024 and FDA authorization materials updated through May 2026.[14] FDA states that before importation can occur, Florida must submit additional drug-specific information for FDA review and approval, testing must verify authenticity and compliance with FDA-approved specifications and standards, and relabeling must be consistent with FDA-approved labeling.[14] This wholesale state-program pathway is separate from individual personal importation.

Policy at the personal-importation layer is also under reconsideration. An executive order signed May 12, 2025 directs HHS to consider issuing the Section 804(l) certification that would activate the Section 804(j) personal-importation provisions.[16] Whether HHS will issue that certification — and what conditions any resulting waiver system would impose — is not determined as of June 8, 2026. A patient building a long-term medication strategy on the assumption that the current framework will continue indefinitely is making a forecast about policy, not relying on a fixed rule.

This page is general information about a federal enforcement posture, based on the FDA’s own published documents. It is not legal advice. Patients with specific legal questions should consult a U.S.-licensed attorney with experience in FDA regulatory or healthcare law.